Eli Lilly and Co to Provide Comprehensive Update on Progress of SARS-CoV-2 Neutralizing Antibody Programs - Conference Call Summary - Thomson StreetEvents

Eli Lilly and Co to Provide Comprehensive Update on Progress of SARS-CoV-2 Neutralizing Antibody Programs - Conference Call Summary

Eli Lilly and Co to Provide Comprehensive Update on Progress of SARS-CoV-2 Neutralizing Antibody Programs - Conference Call Summary - Thomson StreetEvents
Eli Lilly and Co to Provide Comprehensive Update on Progress of SARS-CoV-2 Neutralizing Antibody Programs - Conference Call Summary
Published Oct 07, 2020
22 pages (12825 words) — Published Oct 07, 2020
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of LLY.N conference call or presentation 7-Oct-20 4:00pm GMT

  
Brief Excerpt:

...A. Details: In early days of pandemic, Co. had predicted as did many other experts, that monoclonal antibody therapy could be a high probability way to address moderate and severe patients illness and bridge society to a vaccine. 1. Pursuing this type of technology was also a great fit for Co.'s skills and technology and it could be available in large quantities by the fall, predicting a potential fall surge back in the spring of this year. a. 2. Encouraged by partnership across industry, and collaboration with regulators as Co. collectively moves at unprecedented speed to address the significant challenges set before it. 3. New news complements the progress Co. has already made in developing new treatments for SARS-CoV-2 virus. These include shortening the time to recovery for hospitalized patients using baricitinib in combination with remdesivir in ACTT-2 trial, establishing proof of concept for LY-CoV555 in a Phase 2 trial of patients in ambulatory setting, and partnering with Amgen...

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Eli Lilly and Co
Ticker
LLY.N
Time
4:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

Eli Lilly and Co at Sanford C Bernstein Operational Decisions Conference (Virtual) Transcript – 2020-11-16 – US$ 54.00 – Edited Transcript of LLY.N presentation 16-Nov-20 4:00pm GMT

Eli Lilly and Co Q3 2020 Earnings Call Summary – 2020-10-27 – US$ 54.00 – Edited Brief of LLY.N earnings conference call or presentation 27-Oct-20 1:00pm GMT

Eli Lilly and Co Q3 2020 Earnings Call Transcript – 2020-10-27 – US$ 54.00 – Edited Transcript of LLY.N earnings conference call or presentation 27-Oct-20 1:00pm GMT

Eli Lilly and Co at HMG Live Houston CIO Executive Leadership Summit Transcript – 2020-10-20 – US$ 54.00 – Edited Transcript of LLY.N presentation 20-Oct-20 5:10pm GMT

Eli Lilly and Co to Provide Comprehensive Update on Progress of SARS-CoV-2 Neutralizing Antibody Programs - Conference Call Transcript – 2020-10-07 – US$ 54.00 – Edited Transcript of LLY.N conference call or presentation 7-Oct-20 4:00pm GMT

Eli Lilly and Co to Discuss ESMO 2020 Presentations - Conference Call Transcript – 2020-09-21 – US$ 54.00 – Edited Transcript of LLY.N conference call or presentation 21-Sep-20 7:00pm GMT

Eli Lilly and Co at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript – 2020-09-17 – US$ 54.00 – Edited Transcript of LLY.N presentation 17-Sep-20 12:40pm GMT

Eli Lilly and Co at Morgan Stanley Global Healthcare Conference (Virtual) Transcript – 2020-09-16 – US$ 54.00 – Edited Transcript of LLY.N presentation 16-Sep-20 7:30pm GMT

Eli Lilly and Co Q2 2020 Earnings Call Summary – 2020-07-30 – US$ 54.00 – Edited Brief of LLY.N earnings conference call or presentation 30-Jul-20 1:00pm GMT

Eli Lilly and Co Q2 2020 Earnings Call Transcript – 2020-07-30 – US$ 54.00 – Edited Transcript of LLY.N earnings conference call or presentation 30-Jul-20 1:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Eli Lilly and Co to Provide Comprehensive Update on Progress of SARS-CoV-2 Neutralizing Antibody Programs - Conference Call Summary" Oct 07, 2020. Alacra Store. May 15, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Eli-Lilly-and-Co-to-Provide-Comprehensive-Update-on-Progress-of-SARS-CoV-2-Neutralizing-Antibody-Programs-Conference-Call-B13434839>
  
APA:
Thomson StreetEvents. (2020). Eli Lilly and Co to Provide Comprehensive Update on Progress of SARS-CoV-2 Neutralizing Antibody Programs - Conference Call Summary Oct 07, 2020. New York, NY: Alacra Store. Retrieved May 15, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Eli-Lilly-and-Co-to-Provide-Comprehensive-Update-on-Progress-of-SARS-CoV-2-Neutralizing-Antibody-Programs-Conference-Call-B13434839>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.